Ronald C. Renaud JR - Sep 14, 2021 Form 4 Insider Report for Translate Bio, Inc. (TBIO)

Signature
/s/ Paul D. Burgess, as attorney-in-fact for Ronald C. Renaud, Jr.
Stock symbol
TBIO
Transactions as of
Sep 14, 2021
Transactions value $
-$36,254,014
Form type
4
Date filed
9/14/2021, 07:32 PM
Previous filing
Jun 9, 2021
Next filing
Dec 23, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TBIO Common Stock Sale -$19.1M -503K -100% $38.00 0 Sep 14, 2021 Direct F1
transaction TBIO Common Stock Sale -$15.6M -410K -100% $38.00 0 Sep 14, 2021 By Ronald Renaud 2014 Irrevocable Family Trust F1
transaction TBIO Common Stock Sale -$1.55M -40.9K -100% $38.00 0 Sep 14, 2021 By Ronald C. Renaud, Jr. Trust - 2007 F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TBIO Stock Option (right to buy) Sale $0 -500K -100% $0.00* 0 Sep 14, 2021 Common Stock 500K $7.95 Direct F2, F3
transaction TBIO Stock Option (right to buy) Sale $0 -525K -100% $0.00* 0 Sep 14, 2021 Common Stock 525K $7.66 Direct F2, F4
transaction TBIO Stcok Option (right to buy) Sale $0 -325K -100% $0.00* 0 Sep 14, 2021 Common Stock 325K $23.82 Direct F2, F5
transaction TBIO Stock Option (right to buy) Sale $0 -1.07M -100% $0.00* 0 Sep 14, 2021 Common Stock 1.07M $7.39 Direct F2, F6
transaction TBIO Stock Option (right to buy) Sale $0 -90K -100% $0.00* 0 Sep 14, 2021 Common Stock 90K $8.34 Direct F2, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021.
F2 Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share.
F3 This option was granted on March 8, 2019. This option will vest as to 25% of the shares on March 8, 2020, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 8, 2023.
F4 This option was granted on March 3, 2020. This option will vest as to 25% of the shares on March 3, 2021, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 3, 2024.
F5 This option was granted on March 9, 2021. This option will vest as to 25% of the shares on March 9, 2022, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 9, 2025.
F6 This option was granted on December 22, 2017. The shares underlying became fully vested on March 9, 2021.
F7 This option was granted on March 7, 2018. The shares underlying the option are scheduled to vest over four years, with 25% of the shares vesting on March 7, 2019 and the remainder vesting in equal monthly installment through March 7, 2022.